Triathlon Medical Ventures invests in new class of migraine treatment

Cincinnati's Triathlon Medical Ventures has made another investment in CoLucid Pharmaceuticals, a biotech company focusing on therapies for central nervous system disorders. Triathlon's latest investment is part of a $25 million round of financing to advance a drug to treat migraines. The compound now goes by the name COL-144, and James White, CEO of Indianapolis-based CoLucid, calls it "the first in a new class of migraine therapeutics, representing a paradigm shift in the treatment of migraine."  The drug targets a critical nerve pathway, eliminating some of the potential harmful side effects of previous migraine drugs. Triathlon is venture capital firm founded in Cincinnati in 2004 to focus on life sciences companies, providing equity capital to early-stage firms. Its portfolio includes an investment in Cincinnati-based Akebia Therapeutics.

Writer: David Holthaus
Source: Triathlon Medical Ventures